These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33348949)

  • 1. Erectile disfunction medical treatment with phosphodiesterase 5 inhibitors (PDE5i) in patients with retinitis pigmentosa and side effects.
    Cocci A; Romano A; Morelli G; Frediani D; Sodi A; Russo GI
    Arch Ital Urol Androl; 2020 Dec; 92(4):. PubMed ID: 33348949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
    Shkolyar E; Li S; Tang J; Eisenberg ML
    J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insurance coverage for erectile dysfunction drugs.
    Hornbrook MC; Holup J
    Clin Pharmacol Ther; 2011 Jan; 89(1):19-21. PubMed ID: 21170065
    [No Abstract]   [Full Text] [Related]  

  • 4. First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis.
    Corona G; Rastrelli G; Burri A; Serra E; Gianfrilli D; Mannucci E; Jannini EA; Maggi M
    Andrology; 2016 Nov; 4(6):1002-1009. PubMed ID: 27636710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
    Yafi FA; Sharlip ID; Becher EF
    Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer phosphodiesterase inhibitors: comparison with established agents.
    McNamara ER; Donatucci CF
    Urol Clin North Am; 2011 May; 38(2):155-63. PubMed ID: 21621082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phosphodiesterase-5 inhibitors for erectile dysfunction: Adverse reactions and countermeasures].
    Jiang R; Wu BC
    Zhonghua Nan Ke Xue; 2016 Feb; 22(2):99-103. PubMed ID: 26939391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Relationship Between Phosphodiesterase-5 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy.
    Pomeranz HD
    J Neuroophthalmol; 2016 Jun; 36(2):193-6. PubMed ID: 26720519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
    Munk NE; Knudsen JS; Comerma-Steffensen S; Simonsen U
    Sex Med Rev; 2019 Jul; 7(3):430-441. PubMed ID: 30711478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans.
    Christie A; Vera PL; Higgins M; Kumar S; Lane M; Preston D
    Urology; 2019 Apr; 126():116-120. PubMed ID: 30735744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.
    Gur S; Kadowitz PJ; Gokce A; Sikka SC; Lokman U; Hellstrom WJ
    Curr Drug Metab; 2013 Feb; 14(2):265-9. PubMed ID: 23140258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease.
    Andersson DP; Landucci L; Lagerros YT; Grotta A; Bellocco R; Lehtihet M; Holzmann MJ
    J Am Coll Cardiol; 2021 Mar; 77(12):1535-1550. PubMed ID: 33766260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase-5 inhibitors could be efficacious in the treatment of erectile dysfunction after radiotherapy for prostate cancer: a systematic review and meta-analysis.
    Yang L; Qian S; Liu L; Pu C; Yuan H; Han P; Wei Q
    Urol Int; 2013; 90(3):339-47. PubMed ID: 23221333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.
    Liao X; Qiu S; Bao Y; Wang W; Yang L; Wei Q
    World J Urol; 2019 Jun; 37(6):1061-1074. PubMed ID: 30523399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.
    Jenkins LC; Hall M; Deveci S; Guhring P; Parker M; Nelson CJ; Mulhall JP
    J Sex Med; 2019 Oct; 16(10):1541-1546. PubMed ID: 31444103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?].
    Baydaroglu E; Eschwège P; Hubert J; El Osta R
    Prog Urol; 2019; 29(6):326-331. PubMed ID: 31151915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sexually transmitted infection in HIV-positive men with erectile dysfunction using phosphodiesterase-5 inhibitors.
    McCarty EJ; Quinn K; Dinsmore WW
    Sex Transm Infect; 2011 Oct; 87(6):455. PubMed ID: 21764891
    [No Abstract]   [Full Text] [Related]  

  • 18. [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction].
    Xu Z; Jia RP
    Zhonghua Nan Ke Xue; 2018 Apr; 24(4):355-359. PubMed ID: 30168958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
    Bacconi L; Gressier F
    Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current role of sildenafil in the management of erectile dysfunction].
    Akhvlediani ND; Matyukhov IP
    Urologiia; 2018 May; (2):142-146. PubMed ID: 29901310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.